A large international study of migraine reveals new biological pathways for treatment
REYKJAVIK, Iceland , Oct. 26, 2023. A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 26, 2023 Category: Pharmaceuticals Source Type: clinical trials
First Patient Treated in Multi-Center Pivotal Study of Eye90 microspheres in Hepatocellular Carcinoma
HALIFAX, NS, Oct. 25, 2023. ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the first patient treated in its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 25, 2023 Category: Pharmaceuticals Source Type: clinical trials
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
mRNA-1083 is Moderna ' s first respiratory combination vaccine candidate to enter a Phase 3 trial
Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 24, 2023 Category: Pharmaceuticals Source Type: clinical trials
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
IRVINE, Calif., Oct. 24, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 24, 2023 Category: Pharmaceuticals Source Type: clinical trials
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
PRINCETON, N.J.--(BUSINESS WIRE) Oct 24, 2023 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 24, 2023 Category: Pharmaceuticals Source Type: clinical trials
Datopotamab Deruxtecan Improved Progression-Free Survival vs. Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
23 October 2023 -- Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 23, 2023 Category: Pharmaceuticals Source Type: clinical trials
Phase 3 MARIPOSA-2 Study Shows RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFR-Mutated Non-Small Cell Lung Cancer who Progressed on or after Osimertinib
MADRID, October 23, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced results from the Phase 3 MARIPOSA-2 study showing the regimen of RYBREVANT® (amivantamab-vmjw) given with or without lazertinib and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 23, 2023 Category: Pharmaceuticals Source Type: clinical trials
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT ® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
MADRID, October 23, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced results from the Phase 3 MARIPOSA study showing RYBREVANT® (amivantamab-vmjw) in combination with lazertinib compared to osimertinib... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 23, 2023 Category: Pharmaceuticals Source Type: clinical trials
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival vs. Chemotherapy in Patients with HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
23 October 2023 -- Positive results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 23, 2023 Category: Pharmaceuticals Source Type: clinical trials
AnHeart Therapeutics ’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial
Taletrectinib also shrank tumors in 57 percent of people with ROS1-positive NSCLC who had previously been treated with a ROS1 TKI in the trial
Taletrectinib continues to be generally well tolerated with low incidence of neurological adverse... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
Amgen Presents New Tarlatamab Data In Small Cell Lung Cancer
Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC
Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
Kisqali NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Basel, October 20, 2023. Novartis will present late-breaking results from a prespecified exploratory subgroup analysis of invasive disease-free survival (iDFS) from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
FDA Clears Application to Initiate Phase 1 Clinical Study of oral Immunotherapy for the Treatment of Rheumatoid Arthritis
ROCKVILLE, Md., Oct. 19, 2023. - Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
Nearly 80% of Patients with Moderate-to-Severe Atopic Dermatitis Maintained Clear or Almost Clear Skin with Lilly's Lebrikizumab Monthly Maintenance Dosing at Two Years
INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
Nanoformed TargTex Oncology Drug Candidate TTX101 Receives FDA Orphan Drug Designation
Helsinki, Finland October 19, 2023– Nanoform Finland Plc (Nasdaq Helsinki NANOFH; Nasdaq Stockholm NANOFS), an innovative nanoparticle medicine enabling company, today announced its customer TargTex S.A. has been granted Orphan Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 19, 2023 Category: Pharmaceuticals Source Type: clinical trials
